U.S. markets closed

Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.9200+0.0100 (+1.10%)
At close: 11:58AM EDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.9100
Open0.9200
Bid0.9000 x 0
Ask0.9500 x 0
Day's Range0.8900 - 0.9200
52 Week Range0.2500 - 1.6000
Volume50,015
Avg. Volume46,027
Market Cap129.842M
Beta (5Y Monthly)-0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0550
Earnings DateMar 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Helix BioPharma Corp. Extends Period to Exercise Warrants
      ACCESSWIRE

      Helix BioPharma Corp. Extends Period to Exercise Warrants

      RICHMOND HILL, ON / ACCESSWIRE / April 9, 2021 / Helix BioPharma Corp. (TSX:HBP)(FSE:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has received conditional approval from the Toronto Stock Exchange (the "TSX") to extend the exercise period of a total of 2,837,000 outstanding common share purchase warrants (the "Warrants"), all of which are held by arm's length parties.

    • HBP.TO: LDOS006 New Sites Open
      Zacks Small Cap Research

      HBP.TO: LDOS006 New Sites Open

      By John Vandermosten, CFA TSX:HBP.TO | OTC:HBPCF READ THE FULL HBP.TO RESEARCH REPORT Second Quarter Fiscal Year 2021 Operational and Financial Results Helix BioPharma Corp. (TSX:HBP.TO) (OTC:HBPCF) reported 2Q:21 financial and operational results and submitted its SEDAR filings on March 16, 2021. During fiscal 2Q:21, the three months ended January 31, 2021, Helix executed a definitive agreement

    • Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results
      ACCESSWIRE

      Helix BioPharma Corp. Announces Fiscal Second Quarter 2021 Results

      RICHMOND HILL, ON / ACCESSWIRE / March 16, 2021 / Helix BioPharma Corp. (TSX:"HBP"), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the fiscal second quarter ended January 31, 2021.